Skip to main content

Risk of Psychiatric Adverse Events among Montelukast Users

Basic Details
Date
Type
Publication
Description

There have been conflicting results from observational studies regarding the risk of psychiatric adverse events (PAEs) with montelukast use. The objective of this study was to determine if there are associations of depressive disorders, self-harm and suicide with use of montelukast compared to inhaled corticosteroid (ICS) use.

This publication was also featured as a "Latest Research Summary" in The Journal Of Allergy And Clinical Immunology: In Practice as Risk of Psychiatric Adverse Events following Exposure to Montelukast.

Materials

J Allergy Clin Immunol. 2020 Aug 11. doi.org/10.1016/j.jaip.2020.07.052

Related Assessment(s)
Neuropsychiatric Events Following Montelukast Use: A Propensity Score Matched Analysis
ICPE 2020: Risk of Neuropsychiatric Adverse Events among Montelukast Users
Risk of Psychiatric Adverse Events following Exposure to Montelukast
Author(s)

Veronica V. Sansing-Foster, Nicole Haug, Andrew Mosholder, Noelle M. Cocoros, Marie Bradley, Yong Ma, Dinci Pennap, Elizabeth C. Dee, Sengwee Toh, Ella Pestine, Andrew B. Petrone, Ivone Kim, Jennifer G. Lyons, Efe Eworuke

Corresponding Author

Efe Eworuke; Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
Email: efe.eworuke@fda.hhs.gov